2025-06-03-Jefferies-亚什兰（ASH）_空白领域研发平台是下一个周期的争论点；宏观因素驱动近期发展_11页_435kb

Ashland Inc. (ASH) Equity Research Summary

Rating: BUY with price target of $48.35.

Key Points

• Company Focus: Ashland is a global specialty additives and materials company targeting high-value sectors like personal care, pharma, and specialty additives through innovation and sustainability.
• Financial Outlook: Forecasts 5% sales CAGR through 2027; targets ~$90m EBITDA by 2027, improved margins, and ~$410m cumulative FCF by 2027.
• Investment Thesis: Driven by innovation platforms (e.g., TVOs, bioresorbaWeblP polymers) that support growth and margin expansion, enabled by consistent share buybacks and operational improvements.
• Valuation: Price target $48.35 (based on 13.1x 2027 EPS), trading at a discount to peers like IFF (13.6x EBITDA) and Croda (11.4x EBITDA). Re-rating potential exists under consistent strong performance.
• Risks: Cyclical end markets, raw material volatility, and skepticism over long-term growth.
• Innovation Highlights:
  • TVOs and BioresorbaWeblP polymers for life sciences, pharma, and personal care.
  • Cellulosics tailored for specific applications, with sustainability focus.
  • Super wetting agents and other additives tested in high-growth markets.

Analyst Recommendations

• Equity Research published June 3, 2025; re-rating anticipated as transformation nears completion.

Market Context

• Secular trends like aging populations and rising middle-class demand support growth; peer valuations suggest upside under sustained performance.